Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Ultrasensitive circulating tumor DNA detection improves prognostication in triple-negative breast cancer postneoadjuvant therapy.

286 plasma samples from 86 people in the SCANDARE study were tested with an ultrasensitive tumor-informed whole-genome assay before surgery, during neoadjuvant therapy, and after surgery for stage II-III triple-negative breast cancer. A Personalis author affiliation is on the PubMed record.

ESMO OpenPubMed 42531804DOI 10.1016/j.esmoop.2026.108334